Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
uniQure N.V. (QURE) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/09/2023 8-K Quarterly results
Docs: "uniQure Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress"
08/08/2022 8-K Quarterly results
05/02/2022 8-K Quarterly results
10/25/2021 8-K Quarterly results
Docs: "uniQure Announces Third Quarter 2021 Financial Results and Highlights Recent Company Progress"
07/27/2021 8-K Quarterly results
Docs: "uniQure Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress"
05/10/2021 8-K Quarterly results
10/28/2020 8-K Quarterly results
Docs: "uniQure Announces Third Quarter 2020 Financial Results and Highlights Recent Company Progress ~ Enrolled First Four Patients in Phase I/II Clinical Trial of AMT-130 in Huntington’ s Disease ~ ~ Top-Line Data from HOPE-B Pivotal Trial in Hemophilia B Expected Before Year End ~ ~ Initiated IND-enabling Studies for AMT-150 in Spinocerebellar Ataxia Type 3 ~"
07/31/2020 8-K Quarterly results
04/29/2020 8-K Quarterly results
Docs: "uniQure Announces First Quarter 2020 Financial Results and Highlights Recent Company Progress"
10/28/2019 8-K Quarterly results
07/29/2019 8-K Quarterly results
04/29/2019 8-K Quarterly results
Docs: "uniQure Announces First Quarter 2019 Results and Highlights Recent Company Progress ~ Presented Updated Clinical Data from Phase IIb Study of AMT-061 in Patients with Hemophilia B Demonstrating Increases in FIX Activity Sustained at up to 51% of Normal at 12 Weeks ~ Achieved IND Clearance and Fast Track Designation for AMT-130 in Huntington's disease ~ Announced 6 Presentations at Upcoming ASGCT Meeting, Including Preclinical Data on Research Pipeline"
11/06/2018 8-K Quarterly results
Docs: "uniQure Announces Third Quarter 2018 Financial Results and Highlights Company Progress Lexington, MA and Amsterdam, the Netherlands,"
08/08/2018 8-K Quarterly results
Docs: "uniQure Announces Second Quarter 2018 Financial Results and Highlights Company Progress ~ Patient Enrollment Underway in Global Phase III HOPE-B Pivotal Study of AMT-061 ~ First Patient Successfully Screened into Phase IIb Dose-Confirmation Trial of AMT-061 ~ Robert Gut, M.D., Ph.D., Named Chief Medical Officer and Other Appointments to Clinical Development Leadership ~ Ended Second Quarter with $259 Million in Cash and Cash Equivalents; Expected to Fund Operations into 2021"
08/08/2017 8-K Quarterly results
Docs: "uniQure Announces Second Quarter 2017 Financial Results and Recent Company Progress ~ Advancing Gene Therapy Programs in Hemophilia B and Huntington's Disease ~ ~ Provides Update on Research Collaboration with Bristol-Myers Squibb ~ ~ Makes New Appointments to Company Leadership and Nominations to Board of Directors ~"
05/09/2017 8-K Form 8-K - Current report

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy